Skip to content

Luis E. Contreras

2 papers in the library · publishing 2025-2026

Papers

A scoping review of mystical-type experiences and mood symptom outcomes in psychedelic therapy clinical trials: comparing life-threatening disease and depressive populations

Therapeutic Advances in Psychopharmacology March 1, 2026 Ana Deutsch, Luis E. Contreras, Sarah Kratina et al.

Mystical-type experiences induced by psychedelic therapy are commonly linked to reductions in anxiety and depression symptoms, according to a scoping review of 13 clinical trials involving 410 participants. Among studies with life-threatening disease populations, 80% reported a positive relationship between mystical-type experiences and mood improvement, compared to 63% of studies with depressive populations. The review suggests this relationship may depend on factors like timing of symptom assessments and therapeutic context. Future research should examine variables affecting mystical-type experiences and other aspects of set and setting to optimize positive outcomes.

Exploring Access to Psychedelics Among Canadian Veterans: Pathways, Barriers, and Perceptions

Psychedelic Medicine December 17, 2025 Luis E. Contreras, Grace Elliott, Francesco Kment et al.

Most Canadian military veterans seeking psychedelics for mental health treatment turn to underground sources rather than legal pathways, according to a survey of 30 veterans. Only 20% accessed psychedelics legally, while 64% pursued self-directed experiences and 44% had guided experiences within Canada. Veterans relied primarily on peers (73.3%) and media (53.3%) for information, with only 10% consulting health care providers. Among those who avoided discussing psychedelics with providers, 64% cited concerns about stigma, while 69% who did consult found providers lacked knowledge about psychedelic treatments. These gaps in access and education highlight the need for improved clinician training and policy reform.